Another way to prevent TMPRSS2-mediated SARS-CoV-2 entry is by using chemical protease inhibitors, such as camostat mesylate or nafamostat mesylate (13, 20), also currently in clinical trials against COVID-19 (ClinicalTrials.gov registration no. NCT04418128 and NCT04473053). Here, TMPRSS2 is linked to COVID-19.